运用扶正固本法治疗肝癌靶向治疗后生存质量临床观察40例  

Fuzheng Guben therapy improves quality of life in patients with hepatocellular carcinoma on targeted therapy

作　　者：乔翠霞[1] 张新峰[2] 程旭锋[3] 蔡小平[1] 刘琦[4] 

机构地区：[1]河南省中医药研究院附属医院肿瘤科,河南省郑州市450004 [2]河南省肿瘤医院中西医科,河南省郑州市450000 [3]河南中医学院一附院乳腺科,河南省郑州市450000 [4]河南中医学院科研科,河南省郑州市450000

出　　处：《世界华人消化杂志》2015年第33期5383-5387,共5页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.U1304822~~

摘　　要：目的:观察扶正固本法对肝癌靶向治疗后生存质量.方法:收集2013-01/2015-03河南省中医药研究院附属医院肿瘤科及河南省肿瘤医院中西医科住院及门诊肝癌靶向治疗后患者40例,随机分为两组:治疗组20例、对照组20例,对照组给予索拉非尼的剂量为每次0.4 g,2次/d,空腹,连服2 mo.治疗组在对照组基础上给予中药扶正固本方药煎汤,1剂/d,水煎200 m L,早晚分服,连服2 mo.共治疗2 mo后进行评价患者生存质量.结果:(1)42例患者,2例被剔除,40例纳入本研究,收集完成的病例与脱落病例的数目无统计学上的差异(?2=0.42,P>0.05),患者依从性>97.56%;(2)近期疗效:对照组:部分缓解(partial response,PR)1例(5%)、稳定(stable disease,SD)13例(65%)、进展(progressive disease,PD)6例(30%),客观应答率(overall response rate,ORR)占5%;治疗组:PR 1例(5%)、SD 14例(70%)、PD 5例(25%),ORR占5%.与对照组比较,治疗组RR略升高,但无显著性统计学差异(P=0.792).提示两组治疗方案近期疗效相仿,生存质量方面:两组治疗前ZPS评分未见差异,治疗后治疗组Z P S评分改善、FA C T-G总分治疗组改善明显,差异有统计学意义(P<0.05).结论:扶正固本法对肝癌靶向治疗后近期疗效与单纯靶向治疗比较疗效相当,但联合扶正固本法治疗后患者生存质量显著提高.AIM：To evaluate whether Fuzheng Guben therapy improves quality of life（QoL） in patients with hepatocellular carcinoma（HCC） on targeted therapy.METHODS：A total of 40 patients diagnosed with HCC between January 2013 and March2015 were enrolled into this study.They were randomly and equally divided into either a study group or a control group.The control group was given sorafenib（0.4 g once,twice daily） alone,and the study group was additionally given traditional Chinese medicine Fuzheng Guben soup on the basis of sorafenib therapy.After two months of treatment,the quality of life was evaluated and compared between the two groups.RESULTS：Of the 42 patients,2 discontinued the study and 40 were thus included in the analysis.There was no statistical difference between the two groups in the number of patients who discontinued the study（x^2 = 0.42,P〈0.42）,and the rate of patient compliance was 97.56%.In terms of short-term effect,the control group had 1（5%） case of partial response（PR）,13（65%） cases of stable disease（SD）,and 6（30%） cases of progressive disease（PD）（30%）;the corresponding figures in the study group were 1（5%）,14（70%） and 5（25%）.There was no significant difference between the two groups in overall response rate（ORR）（5%vs 5%,P〈0.05）.With regards to quality of life,there was no significant difference in ZPS score between the two groups before treatment;after treatment,ZPS score was improved and FACT-G score was improved significantly in the study group（P〈0.05）.CONCLUSION：Fuzheng Guben therapy improves QoL in patients with HCC on targeted therapy.

关 键 词：扶正固本法 肝癌 生存质量 

分 类 号：R735.7[医药卫生—肿瘤]